Xencor Q4 net loss widens to $45.6M; full-year revenue falls 37% to $110.5M

Xencor Inc

2024-FY EPS reported -$3.58 revenue$110,493,000

Q4 revenue $52.8M (+3.5% YoY) driven by milestone payments; full-year revenue $110.5M vs $174.6M.
FY 2024 net loss $232.6M ($3.58 diluted EPS) vs $133.1M ($2.20); R&D spend dropped to $227.7M.
Cash $706.7M at Dec 31; 2025 guidance $535-585M, runway into 2028.
Pipeline: XmAb942 healthy-volunteer data 1H 2025; XmAb819 ccRCC data 2H 2025; plamotamab RA Ph1b/2a start 1H 2025.
Vudalimab development paused; milestone revenue of $30M (Amgen) and $4M (Novartis) received in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.